checkAd

     113  0 Kommentare Novo Integrated Sciences Receives Confirmation of Issuance of SBLC by HSBC for SBLC Leasing and Monetizing Program

    Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) announced today that it has received confirmation of the issuance of a Standby Letter of Credit (“SBLC”) by HSBC for delivery by Swift MT760, as part of a program designed for monetizing SBLCs. As previously reported, the Company entered into an application for the monetizing program whereby the Company is projected to receive gross funding proceeds of approximately $78 million under the SBLC upon completion of monetization.

    The Company expects to use the proceeds to close the acquisition of the Ophir Collection which will result in the sole unfettered ownership of the Ophir Collection by the Company.

    "The issuance of the MT760 is the final step prior to monetization. It is exciting to see the progress leading us toward the Ophir Collection acquisition, as well as providing additional funds directed to the previously reported share repurchase program. Our commitment to raising non-dilutive capital for the Company remains foremost in our efforts as we consider uniquely advantageous funding sources,” stated Robert Mattacchione, the Company’s CEO and Board Chairman.

    About Novo Integrated Sciences, Inc.

    Novo Integrated Sciences, Inc. is pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of services and product innovation. Novo offers an essential and differentiated solution to deliver, or intend to deliver, these services and products through the integration of medical technology, advanced therapeutics, and rehabilitative science.

    We believe that “decentralizing” healthcare, through the integration of medical technology and interconnectivity, is an essential solution to the rapidly evolving fundamental transformation of how non-catastrophic healthcare is delivered both now and in the future. Specific to non-critical care, ongoing advancements in both medical technology and inter-connectivity are allowing for a shift of the patient/practitioner relationship to the patient’s home and away from on-site visits to primary medical centers with mass-services. This acceleration of “ease-of-access” in the patient/practitioner interaction for non-critical care diagnosis and subsequent treatment minimizes the degradation of non-critical health conditions to critical conditions as well as allowing for more cost-effective healthcare distribution.

    Seite 1 von 3



    Business Wire (engl.)
    0 Follower
    Autor folgen

    Novo Integrated Sciences Receives Confirmation of Issuance of SBLC by HSBC for SBLC Leasing and Monetizing Program Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”) announced today that it has received confirmation of the issuance of a Standby Letter of Credit (“SBLC”) by HSBC for delivery by Swift MT760, as part of a program designed for …